Lantheus Reports Preliminary Fiscal Year 2023 Revenue
09 Janeiro 2024 - 9:55AM
Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading
radiopharmaceutical-focused company committed to enabling
clinicians to Find, Fight and Follow disease to deliver better
patient outcomes, today reported certain preliminary unaudited
financial results for its fiscal year ended December 31, 2023.
Full Year 2023 Revenue Highlights |
|
Year Ended Dec. 31, 2023 |
Year Ended Dec. 31, 2022 |
YoY Change |
Worldwide Revenue |
$1.295 – 1.297 billion |
$935.1 million |
+38 - 39% |
PYLARIFY Revenue |
$851 – 853 million |
$527.4 million |
+61 - 62% |
“Lantheus has consistently exemplified our strong commitment to
excellence and has been at the forefront in the ongoing renaissance
in the radiopharmaceutical industry,” stated Mary Anne Heino, Chief
Executive Officer of Lantheus. “Over the course of the past year,
Lantheus has impacted the lives of more than six million patients
and their families. Our efforts have resulted in record revenues
and a period of exceptional achievement. As we head into 2024,
Lantheus is well positioned for growth and to deliver sustained
shareholder value, driven by our radiopharmaceutical platform and
supported by the dedicated efforts of the Lantheus team to Find,
Fight and Follow disease to deliver better patient outcomes.”
Fiscal Year 2023 Revenue
- Worldwide revenue for the full year 2023 is expected to be in
the range of $1.295 - 1.297 billion, compared with $0.935 billion
for the full year 2022, which would represent an increase of
approximately 38 - 39% over the prior year period, exceeding the
Company’s previously issued guidance range of $1.255 - 1.270
billion;
- Expected worldwide revenue for the full year 2023, excluding
the RELISTOR sales milestone of $15 million, represents an increase
of approximately 37% over the prior year period;
- PYLARIFY revenue for the full year 2023 is expected to be in
the range of $851 - 853 million, pending final partner
reconciliation, compared with $527.4 million for full year 2022,
which represents an increase of approximately 61 - 62%; and
- DEFINITY revenue for the full year 2023 is expected to be
approximately $279 million, compared with $245 million for full
year 2022, which represents an increase of approximately 14%.
These preliminary results are unaudited and remain subject to
adjustment. Lantheus will provide its fourth quarter and full year
2023 financial results, and further details related to its 2024
financial expectations, in late February 2024.
About LantheusLantheus is the leading
radiopharmaceutical-focused company, delivering life-changing
science to enable clinicians to Find, Fight and Follow disease to
deliver better patient outcomes. Headquartered in Massachusetts
with offices in New Jersey, Canada and Sweden, Lantheus has been
providing radiopharmaceutical solutions for more than 65 years. For
more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, that are subject to risks and uncertainties and
are made pursuant to the safe harbor provisions of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements may be identified by their use of terms such as
“anticipate,” “believe,” “confident,” “continue,” “could,”
“estimate,” “expect,” “guidance,” “intend,” “introduce,” “may,”
“momentum,” “plan,” “potential,” “predict,” “progress,” “project,”
“promising,” “should,” “target,” “will,” “would” and other similar
terms. Such forward-looking statements include our preliminary
revenue results for fiscal year 2023 and are based upon current
plans, estimates and expectations that are subject to risks and
uncertainties that could cause actual results to materially differ
from those described in the forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation that such plans, estimates and expectations will be
achieved. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law. Risks and uncertainties that could cause our
actual results to materially differ from those described in the
forward-looking statements include: (i) continued market expansion
and penetration for our established commercial products,
particularly PYLARIFY and DEFINITY, in a competitive environment in
which other imaging agents have been approved and are being
commercialized, and our ability to clinically and commercially
differentiate our products from other products; (ii) our ability to
have third parties manufacture our products and our ability to
manufacture DEFINITY in our in-house manufacturing facility; (iii)
the global availability of Molybdenum-99 (“Mo-99”) and other raw
material and key components; (iv) the efforts and timing for
clinical development, regulatory approval and successful
commercialization of our product candidates and new clinical
applications and territories for our products, in each case, that
we or our strategic partners may undertake; (v) our strategies,
future prospects, and our projected growth, including revenue
related to our collaboration agreements with POINT Biopharma Global
Inc.; (vi) our ability to successfully continue existing clinical
development partnerships using MK-6240 as a research tool and to
further develop and commercialize such research tool; (vii) our
ability to identify and acquire or in-license additional diagnostic
and therapeutic product opportunities in oncology and other
strategic areas and continue to grow our pipeline of products; and
(viii) the risk and uncertainties discussed in our filings with the
Securities and Exchange Commission (including those described in
the Risk Factors section in our Annual Reports on Form 10-K and our
Quarterly Reports on Form 10-Q).
Contacts:Mark Kinarney Vice President,
Investor Relations 978-671-8842 ir@lantheus.com
Melissa Downs Senior Director, External
Communications 646-975-2533 media@lantheus.com
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024